Q702 for the Treatment of Patients With Hematologic Malignancies
NCT06712810 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 46
Last updated 2025-10-10
Summary
This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Giving Q702 may be safe, tolerable and/or effective in treating patients with hematologic malignancies.
Conditions
- Hematopoietic and Lymphatic System Neoplasm
- Histiocytic Sarcoma
- Malignant Histiocytosis
- Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Chronic Myelomonocytic Leukemia
- Recurrent Follicular Lymphoma
- Recurrent Langerhans Cell Histiocytosis
- Recurrent Lymphoplasmacytic Lymphoma
- Recurrent Myelodysplastic Syndrome
- Recurrent Myelofibrosis
- Recurrent Small Lymphocytic Lymphoma
- Recurrent Waldenstrom Macroglobulinemia
- Refractory Chronic Lymphocytic Leukemia
- Refractory Chronic Myelomonocytic Leukemia
- Refractory Erdheim-Chester Disease
- Refractory Follicular Lymphoma
- Refractory Langerhans Cell Histiocytosis
- Refractory Lymphoplasmacytic Lymphoma
- Refractory Myelodysplastic Syndrome
- Refractory Myelofibrosis
- Refractory Small Lymphocytic Lymphoma
- Refractory Waldenstrom Macroglobulinemia
- Rosai-Dorfman-Destombes Disease
- Primary Central Nervous System Lymphoma
- Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
- Recurrent Erdheim-Chester Disease
- Recurrent Fibroblastic Reticular Cell Sarcoma
- Recurrent Histiocytic Sarcoma
- Recurrent Interdigitating Dendritic Cell Sarcoma
- Recurrent Rosai-Dorfman-Destombes Disease
- Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
- Refractory Fibroblastic Reticular Cell Sarcoma
- Refractory Histiocytic Sarcoma
- Refractory Interdigitating Dendritic Cell Sarcoma
- Refractory Rosai-Dorfman-Destombes Disease
Interventions
- DRUG
-
Axl/Mer/CSF1R Inhibitor Q702
Given PO
- PROCEDURE
-
Biospecimen Collection
Undergo blood and urine sample collection
- PROCEDURE
-
Bone Marrow Aspiration
Undergo bone marrow biopsy and aspiration
- PROCEDURE
-
Bone Marrow Biopsy
Undergo bone marrow biopsy and aspiration
- PROCEDURE
-
Computed Tomography
Undergo CT scan
- PROCEDURE
-
Magnetic Resonance Imaging
Undergo MRI
- PROCEDURE
-
Positron Emission Tomography
Undergo PET scan
- OTHER
-
Survey Administration
Ancillary study
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Jithma P. Abeykoon, MD · Mayo Clinic in Rochester
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-08-27
- Primary Completion
- 2030-09-15
- Completion
- 2030-09-15
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma
NCT01200758 ·Status: COMPLETED ·Phase: PHASE3
-
Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma
NCT03189836 ·Status: TERMINATED ·Phase: PHASE1
-
Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)
NCT00562965 ·Status: TERMINATED ·Phase: PHASE3
-
Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma
NCT02532257 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma
NCT01209130 ·Status: COMPLETED ·Phase: PHASE1
-
Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
NCT00288067 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT05626322 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
NCT00670358 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL
NCT06832267 ·Status: RECRUITING ·Phase: NA
-
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma
NCT00867529 ·Status: COMPLETED ·Phase: PHASE2
-
Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05875428 ·Status: UNKNOWN ·Phase: PHASE2
-
DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis
NCT00515788 ·Status: TERMINATED ·Phase: PHASE1
-
Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
NCT00720135 ·Status: COMPLETED ·Phase: PHASE1
-
TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT05507541 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Outpatient Epcoritamab as 2L in NTE R/R DLBCL
NCT06811272 ·Status: RECRUITING ·Phase: PHASE2
-
Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma
NCT00784927 ·Status: COMPLETED ·Phase: PHASE2
-
Phase Ib Study of Rocbrutinib in Combination with R-CHOP in Patients with Newly Diagnosed B-cell Non-Hodgkin Lymphoma
NCT06251180 ·Status: RECRUITING ·Phase: PHASE1
-
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
NCT03571828 ·Status: TERMINATED ·Phase: PHASE1
-
Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma
NCT07022223 ·Status: RECRUITING ·Phase: PHASE2
-
Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma
NCT00290667 ·Status: COMPLETED ·Phase: PHASE2
-
A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)
NCT04660799 ·Status: COMPLETED ·Phase: PHASE2
-
Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma
NCT02113007 ·Status: TERMINATED ·Phase: PHASE2
-
Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma
NCT00008021 ·Status: UNKNOWN ·Phase: PHASE1
-
A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System
NCT06385522 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma
NCT01653067 ·Status: UNKNOWN ·Phase: PHASE2